Boston Scientific Corporation (NYSE:BSX) reported first-quarter 2026 revenues of $5.20 billion on Wednesday, slightly better than the consensus estimate of $5.17 billion, beating the management guidance of $5.22 billion-$5.31 billion.
Sales increased 11.6% on a reported basis, within the company’s guidance range of 10.5%-12%, and 9.4% on an operational and organic basis, within the company’s guidance range of 8.5%-10%.
The medical technology giant reported adjusted earnings of 80 cents, beating the consensus of 79 cents and the management guidance of 78-80 cents.
Boston Scientific Cardiovascular Segment Drives Double-Digit Growth
The revenue growth was driven primarily by strong performance in its Cardiovascular segment, which generated $3.503 billion in revenue with 11% organic growth.
The …